This study is a single-center, open-label, single-dose phase I clinical trial. The trial is divided into four periods: screening, baseline, treatment, and follow-up
Informed consent was obtained voluntarily
Healthy males aged 18 ~ 45 years (inclusive)
Body weight ≥50 kg, BMI 19 ~ 28 kg/m2 (inclusive)
Adopt efficient contraceptive measures
Have a history of drug allergy, specific allergy, or allergic constitution
Any previous or current medical history that may affect the safety of the participant in the trial or the course of the study drug in vivo
Have a history of risk factors for torsade de pointes
During the screening period, serum potassium, sodium, ALT, or AST were beyond the normal range, or the calculated eGFR was less than 90 mL/min/1.73m2